Gilead Sciences | GILD - Equity Capital And Reserves



Gilead Sciences reported $19.67B in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.


Equity Capital And Reserves Change Date
AbbVie USD 1.46B 1.86B Mar/2025
Agios Pharmaceuticals USD 1.37B 96.97M Jun/2025
ALKERMES USD 1.62B 113M Jun/2025
Alnylam Pharmaceuticals USD 250.59M 135.16M Jun/2025
Amgen USD 7.43B 1.22B Jun/2025
Biogen USD 17.63B 655.3M Jun/2025
BioMarin Pharmaceutical USD 6.03B 233.65M Jun/2025
Bristol-Myers Squibb USD 17.49B 100M Jun/2025
Eli Lilly USD 18.27B 2.43B Jun/2025
Gilead Sciences USD 19.67B 596M Jun/2025
GlaxoSmithKline GBP 14.35B 197M Jun/2025
Glaxosmithkline GBP 14.35B 683M Jun/2025
Incyte USD 4.17B 503.34M Jun/2025
J&J USD 78.11B 6.62B Mar/2025
Merck USD 49.06B 725M Jun/2025
Moderna USD 9.4B 667M Jun/2025
Neurocrine Biosciences USD 2.69B 158.6M Jun/2025
Novartis USD 42.05B 3.6B Jun/2025
Pfizer USD 88.7B 1.64B Jun/2025
PTC Therapeutics USD -206546000 20.79M Jun/2025
Regeneron Pharmaceuticals USD 29.94B 551.3M Jun/2025
Sanofi 70.28B 3.8B Jun/2025
Sarepta Therapeutics USD 1.36B 214.66M Jun/2025
United Therapeutics USD 7.17B 366.4M Jun/2025
Vertex Pharmaceuticals USD 17.18B 679.1M Jun/2025